Neurogene Inc.NGNENASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating

Buy

5 analysts·Limited coverage

80%

Rating Distribution

Strong Buy

00%

Buy

480%

Hold

120%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 164% higher.

Bear Case

$45.00

+164%

Consensus

$45.00

+164%

Bull Case

$45.00

+164%

Price Range5 analysts

Low

Consensus

High

$45.00

Current Target

Current Price

$17.03

Upside to Target

$27.97

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-5.01(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+100.00%

EPS—

FY2028

Rev+8221.68%

EPS—

FY2029

Rev+238.49%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+25.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 2, 2025H.C. Wainwright

Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright

Target:$45.00

+118.3%from $20.61

Apr 14, 2025BMO Capital

Neurogene price target lowered to $16 from $45 at BMO Capital

Target:$16.00

+46.9%from $10.89

Mar 25, 2025Robert W. Baird

Neurogene price target lowered to $38 from $46 at Baird

Target:$38.00

+167.6%from $14.20

Mar 25, 2025H.C. Wainwright

Neurogene price target lowered to $50 from $55 at H.C. Wainwright

Target:$50.00

+252.1%from $14.20

Nov 20, 2024Stifel Nicolaus

Neurogene (NGNE) PT Lowered to $46 at Stifel

Target:$46.00

+200.1%from $15.33

Nov 19, 2024BMO Capital

Neurogene (NGNE) PT Lowered to $45 at BMO Capital

Target:$45.00

+26.4%from $35.59

Nov 12, 2024BMO Capital

Neurogene (NGNE) PT Lowered to $60 at BMO Capital

Target:$60.00

-6.9%from $64.48

Nov 12, 2024Stifel Nicolaus

Neurogene (NGNE) PT Raised to $60 at Stifel

Target:$60.00

-6.9%from $64.48

Aug 12, 2024H.C. Wainwright

Neurogene price target lowered to $49 from $51 at H.C. Wainwright

Target:$49.00

+37.7%from $35.59

Jun 26, 2024BMO Capital

BMO Capital Starts Neurogene (NGNE) at Outperform

Target:$65.00

+103.1%from $32.01

Jun 10, 2024Robert W. Baird

Baird Starts Neurogene (NGNE) at Outperform

Target:$54.00

+44.6%from $37.35

May 13, 2024H.C. Wainwright

Neurogene (NGNE) PT Lowered to $51 at H.C. Wainwright

Target:$51.00

+68.5%from $30.26

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance